Get the Stockscreener App
76.56
3.74%
2.76
After Hours:
76.54
-0.02
-0.03%
Moderna Inc stock is traded at $76.56, with a volume of 4.34M.
It is up +3.74% in the last 24 hours and up +60.40% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$73.80
Open:
$73.8
24h Volume:
4.34M
Relative Volume:
0.60
Market Cap:
$30.38B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-9.3982
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
-4.01%
1M Performance:
+60.40%
6M Performance:
+123.21%
1Y Performance:
+133.49%
1-Day Range:
$73.14
$76.84
1-Week Range:
$73.14
$85.60
52-Week Range:
$22.28
$85.60
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
76.56 | 29.28B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
496.50 | 126.50B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.95 | 69.50B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
909.49 | 56.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.79 | 43.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.13 | 40.34B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Why Moderna (MRNA) Stock Is Trading Up Today - TradingView
Moderna secures up to 24 million RSV vaccine dose contract with Europe - Pharmaceutical Technology
Moderna wins EU contract for RSV vaccine supply - Reuters
Moderna Stock Drops After Morgan Stanley Sticks To Neutral Rating Despite Lifting Price Target - TIKR.com
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026 - ACCESS Newswire
Moderna schedules July 31 results call and corporate update - Stock Titan
RBC Capital Raises its Price Target on Moderna (MRNA) - Insider Monkey
Will New Board Appointment And mRNA Flu Progress Change Moderna's (MRNA) Pipeline Diversification Narrative? - Yahoo Finance
Moderna Appoints Michael McDonnell to Board of Directors - Investing News Network
Moderna (MRNA) Settles Vaccine Patent Case With $950 Million Upfront Payment - simplywall.st
MRNA Maintained by Morgan Stanley -- Price Target Raised to $39 - GuruFocus
MRNA Stock Heads to $60 as Investors Liquidate after New Moderna Board Appointment Announcement - FXLeaders
Moderna (MRNA) Welcomes Michael McDonnell to Board of Directors - GuruFocus
Why Moderna Stock Is the S&P 500’s Big Loser Today - Barron's
Moderna appoints Michael McDonnell to board; shares retreat from 52-week high - Seeking Alpha
Moderna (MRNA) Appoints Michael McDonnell to Board of Directors - GuruFocus
Moderna Inc outlines its next phase. MRNA pivots beyond Covid vaccines - Ad-hoc-news.de
Moderna Strengthens Board with New Financial Director - TipRanks
Moderna Inc. focuses on mRNA pipeline as investors watch Nasdaq trading - Ad-hoc-news.de
Moderna adds former Biogen CFO to board of directors By Investing.com - Investing.com Canada
Former Biogen CFO Michael McDonnell joins Moderna (NASDAQ: MRNA) board and Audit Committee - Stock Titan
Moderna, Inc. Announces Board and Committee Changes, Effective July 8, 2026 - marketscreener.com
Moderna adds former Biogen CFO Michael McDonnell to its board - Stock Titan
Bank of America Securities Reaffirms Their Sell Rating on Moderna (MRNA) - The Globe and Mail
The Moderna Omicron XBB.1.5 vaccine. Updated booster targets current variants - AD HOC NEWS
Meitav Investment House Ltd. Sells 16,067 Shares of Moderna, Inc. $MRNA - MarketBeat
Morgan Stanley Adjusts Price Target Moderna to $39 From $33, Maintains Equalweight Rating - marketscreener.com
Hsbc Holdings PLC Sells 107,077 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Stock Surges 37%, With A 6-Day Winning Spree - Trefis
Moderna Stock On Fire: Up 37% With 6-Day Winning Streak - Trefis
Form 4 Moderna Inc For: 7 July By Investing.com - Investing.com Canada
Moderna (MRNA) Chief Commercial Officer awarded RSUs and stock options - Stock Titan
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week - Yahoo Finance
MRNA Maintained by RBC Capital -- Price Target Raised to $45 - GuruFocus
MRNA Maintained by B of A Securities -- Price Target Raised to $38 - GuruFocus
Strs Ohio Acquires 68,887 Shares of Moderna, Inc. $MRNA - MarketBeat
RBC Capital Adjusts Moderna Price Target to $45 From $38, Maintains Sector Perform Rating - marketscreener.com
Moderna Stock Is Soaring. Is It Too Late to Buy? - The Motley Fool
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Moderna (MRNA) CFO reports RSU vesting, tax-withheld shares on Form 4 - Stock Titan
Moderna (NASDAQ:MRNA) Vaccine Momentum Turns Heads - Kalkine Media
Moderna shares rise as investors continue to digest pipeline expansion and flu vaccine progress - Quiver Quantitative
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna stock hits 52-week high at 81.42 USD - Investing.com
17,700 Shares in Moderna, Inc. $MRNA Bought by Louisiana State Employees Retirement System - MarketBeat
Price to sales forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
MRNA Stock Quote Price and Forecast - CNN
Moderna | History, Innovation, Challenges, & Facts - Encyclopedia Britannica
Jim Cramer Turns Bullish on Moderna After 150% Rally, Citing Cancer Pipeline and Flu Vaccine Momentum - finance.biggo.com
Jim Cramer Says “For the First Time in Ages, I Like Having a Position in Moderna” - Yahoo Finance
MRNAModerna Inc Latest SEC Filings - Finviz
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):